N/A N=1,015 CoreValve Advance International Post Market Study
Severe Aortic Stenosis
Primary: Major Adverse Cardiac & Cerebrovascular Events (MACCE) — 92 Freedom from MACCE (%) @30days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=100 ADVANCE Direct Aortic Study
Aortic Stenosis · Valvular Heart Disease
Primary: All-cause Mortality — 4.4 Percentage of subjects
N/A N=200 CoreValve Advance-II Study: Prospective International Post-market Study
Aortic Valve Stenosis · Valvular Heart Disease
Primary: New-onset Class I or II Indication for Permanent Pacemaker Implantation — 13.3; 21.4 Percentage of subjects
N/A N=95 ADvanced Hybrid Closed Loop Study in Adult Population With Type 1 Diabetes
Type 1 Diabetes
Primary: HbA1c 6 Months Change Between AHCL and MDI — -1.54; -0.20 Percentage of HbA1c — p=<0.0001
N/A N=80 AMS AdVance and AdVance XP Male Sling Systems for the Treatment of Stress Urinary Incontinence Following Prostatectomy: Evaluation of Safety, Efficacy, and Quality of Life Through Retrospective Chart Review and Prospective Follow-up
Urinary Incontinence, Stress · Intrinsic Sphincter Deficiency
Primary: Percentage of Subjects With a ≥50% Reduction in Pads Per Day Use — 87.2; 97.6 percentage of participants
Phase 2 N=6 Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency
Alpha 1-Antitrypsin Deficiency
Primary: Treatment-emergent Adverse Events Related to ADVM-043 — 0; 1; 2 Participants
N/A N=161 Patient and Provider Glucose Reporting Preferences Ambulatory Glucose Profile (AGP)
Type 1 Diabetes
Primary: Portion of Study Participants Reporting Greater Utility From AGP vs. Traditional Glucose Data Reports — 35; 29; 10 participants
N/A N=34 Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)
Type 1 Diabetes
Primary: Number of Severe Hypoglycemic Events — 0 events